BACKGROUND: Mycophenolate mofetil (MMF) use in renal transplantation has steadily increased since 1995 because of its ability to lower the risks of rejection and chronic allograft nephropathy. However, significant gastrointestinal (GI) complications may lead to MMF dose reductions and discontinuations. Little is known of the association between MMF dose reductions and discontinuations following GI complications and graft survival. METHODS: Using the United States Renal Data System, we identified 3,675 adult recipients (age >or=18) with a diagnosed GI complication who were prescribed MMF at the time of first GI diagnosis and had Medicare as their primary insurer. MMF doses were ascertained from Medicare payment records. We estimated risk of graft loss associated with MMF dose adjustments after GI diagnosis: dosage unchanged (reference), reduced <50%, reduced >or=50%, and MMF discontinued. Patients were followed until graft loss, death, last recorded immunosuppression prescription, or 3 years posttransplant. RESULTS: Compared to those with no MMF dose reductions or discontinuations, the risk of graft failure increased with MMF doses reduction >or=50% (HR=2.36, 95% CI 1.23-4.54) and those with MMF discontinuation (2.72, CI 1.60-4.64). CONCLUSION: Renal transplant recipients who underwent MMF dose reduction or withdrawal following GI diagnosis are associated with increased risk of graft failure.
BACKGROUND:Mycophenolate mofetil (MMF) use in renal transplantation has steadily increased since 1995 because of its ability to lower the risks of rejection and chronic allograft nephropathy. However, significant gastrointestinal (GI) complications may lead to MMF dose reductions and discontinuations. Little is known of the association between MMF dose reductions and discontinuations following GI complications and graft survival. METHODS: Using the United States Renal Data System, we identified 3,675 adult recipients (age >or=18) with a diagnosed GI complication who were prescribed MMF at the time of first GI diagnosis and had Medicare as their primary insurer. MMF doses were ascertained from Medicare payment records. We estimated risk of graft loss associated with MMF dose adjustments after GI diagnosis: dosage unchanged (reference), reduced <50%, reduced >or=50%, and MMF discontinued. Patients were followed until graft loss, death, last recorded immunosuppression prescription, or 3 years posttransplant. RESULTS: Compared to those with no MMF dose reductions or discontinuations, the risk of graft failure increased with MMF doses reduction >or=50% (HR=2.36, 95% CI 1.23-4.54) and those with MMF discontinuation (2.72, CI 1.60-4.64). CONCLUSION: Renal transplant recipients who underwent MMF dose reduction or withdrawal following GI diagnosis are associated with increased risk of graft failure.
Authors: Erin L Ohmann; Gilbert J Burckart; Yan Chen; Vera Pravica; Maria M Brooks; Adriana Zeevi; Steven A Webber Journal: Pediatr Transplant Date: 2010-11
Authors: John Richard Lee; Matthew Magruder; Lisa Zhang; Lars F Westblade; Michael J Satlin; Amy Robertson; Emmanuel Edusei; Carl Crawford; Lilan Ling; Ying Taur; Jonas Schluter; Michelle Lubetzky; Darshana Dadhania; Eric Pamer; Manikkam Suthanthiran Journal: Am J Transplant Date: 2018-07-21 Impact factor: 8.086
Authors: Gilbert J Burckart; William D Figg; Maria M Brooks; Dionna J Green; Sarah M Troutman; Robert Ferrell; Richard Chinnock; Charles Canter; Linda Addonizio; Daniel Bernstein; James K Kirklin; David Naftel; Douglas K Price; Tristan M Sissung; Diana M Girnita; Adriana Zeevi; Steven A Webber Journal: J Pediatr Pharmacol Ther Date: 2014-01
Authors: Hyeon Seok Hwang; Bok Jin Hyoung; Sol Kim; Ha Young Oh; Yon Su Kim; Jung Kyung Kim; Yeong Hoon Kim; Yong Lim Kim; Chan Duck Kim; Gyu Tae Shin; Chul Woo Yang Journal: J Korean Med Sci Date: 2010-11-24 Impact factor: 2.153
Authors: Ignacio A Echenique; Sudhir Penugonda; Valentina Stosor; Michael G Ison; Michael P Angarone Journal: Clin Infect Dis Date: 2014-11-03 Impact factor: 9.079